AstraZeneca Leading the Covid-19 Vaccine Race; May Get Results Quite Early: WHO

AstraZeneca Leading the Covid-19 Vaccine Race; May Get Results Quite Early: WHO
The World Health Organization said on Friday that AstraZeneca's experimental Covid-19 vaccine is the world’s leading candidate and reached the final stage in terms of development, Reuters reported.AstraZeneca, a potential vaccine for coronavirus which is being developed by the researchers at the University of Oxford, has entered in large-scale,...

The World Health Organization said on Friday that AstraZeneca's experimental Covid-19 vaccine is the world’s leading candidate and reached the final stage in terms of development, Reuters reported.

AstraZeneca, a potential vaccine for coronavirus which is being developed by the researchers at the University of Oxford, has entered in large-scale, mid-stage human trials of the vaccine. This week, AstraZeneca signed its tenth supply-and-manufacturing deal.

"Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate," WHO chief scientist Soumya Swaminathan told a news conference.

"So it's possible they will have results quite early."

Swaminathan said Moderna's Covid-19 vaccine candidate was "not far behind" AstraZeneca's, among more than 200 candidates, 15 of which have entered clinical trials.

"We do know that Moderna's vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind," she said cited as saying in the Reuters report.

"But I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials."

WHO is in talks with various vaccine manufacture

The WHO is in talks with multiple Chinese manufacturers, including Sinovac, on potential vaccines, as well as with Indian researchers, Swaminathan said.

She also urged drugmakers to extend their support to the developers by collaborating on Covid-19 vaccine trials, similar to the WHO's ongoing Solidarity trial for drugs.

A WHO-led coalition fighting the pandemic on Friday asked the government and private sector donors to help raise $31.3 billion in the next 12 months to develop and deliver tests, treatments, and vaccines for the disease. The initiative is called the ACT-Accelerator.

Andrew Witty, Special Envoy for the ACT-Accelerator, said it was important to consider a "portfolio of research efforts" for vaccines.

"It's still very early days in this journey, we may be super lucky - which would be terrific - and have an early win," Witty said. "Even if it takes 12 to 18 months that would be without precedent, the world's fast development of a vaccine."

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill.

In these difficult times, we, at BusinessLine, are trying our best to ensure the newspaper reaches your hands every day. You can also access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all our readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. You can help us by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section.

Our subscriptions start as low as Rs 199/- per month. A yearly package costs just Rs. 999 – a mere Rs 2.75 per day, less than a third the price of a cup of roadside chai..

A little help from you can make a huge difference to the cause of quality journalism!

coronavirus

Source: www.thehindubusinessline.com